RNA, U4 small nuclear 38, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-38P profile across patient tissues and cancer cell-line models. RNU4-38P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU4-38P is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, RNU4-38P RNA expression shows 11,215 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, STAD, and LUAD as cancer lineages where RNU4-38P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-38P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-38P survival associations across molecular data types. RNU4-38P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-38P RNA expression–survival associations across cancer types. High RNU4-38P expression shows unfavorable associations in KIRP, ESCA, THCA, DLBC and READ, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU4-38P RNA expression.
This table summarizes RNU4-38P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-38P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-38P shows lower tumor expression in THCA and higher tumor expression in STAD, BRCA, PRAD and HNSC. The STAD box plot shows higher RNU4-38P RNA expression in tumor versus normal tissue (log2 FC = +0.700, t-test p < 0.001).
This table shows molecular features associated with RNU4-38P in patient tissues and cancer cell lines. In patient samples, RNU4-38P shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
